Growth Metrics

Genmab A (GMAB) Cost of Revenue (2024 - 2025)

Historic Cost of Revenue for Genmab A (GMAB) over the last 2 years, with Q4 2025 value amounting to -$157.0 million.

  • Genmab A's Cost of Revenue fell 42708.28% to -$157.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $238.0, marking a year-over-year decrease of 9999.98%. This contributed to the annual value of $238.0 for FY2025, which is 9999.98% down from last year.
  • According to the latest figures from Q4 2025, Genmab A's Cost of Revenue is -$157.0 million, which was down 42708.28% from $58.0 million recorded in Q3 2025.
  • In the past 5 years, Genmab A's Cost of Revenue ranged from a high of $58.0 million in Q3 2025 and a low of -$157.0 million during Q4 2025